Company Description
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.
The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.
The company was founded in 2017 and is headquartered in New York, New York.
Country | United States |
Founded | 2017 |
IPO Date | Nov 3, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 72 |
CEO | R. Townsend |
Contact Details
Address: 345 Park Avenue South, 6th Floor New York, New York 10010 United States | |
Phone | 212 547 9879 |
Website | lexeotx.com |
Stock Details
Ticker Symbol | LXEO |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $11.00 |
CIK Code | 0001907108 |
CUSIP Number | 52886X107 |
ISIN Number | US52886X1072 |
Employer ID | 85-4012572 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
R. Nolan Townsend | Chief Executive Officer and Director |
Dr. Eric Adler M.D. | Chief Medical Officer and Head of Research |
Jenny R. Robertson J.D. | Chief Legal Officer |
Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board |
Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Financial Officer |
Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
Jordan M. Baumhardt Ph.D. | Vice President of Corporate Development |
Dr. Sandi See Tai M.D. | Chief Development Officer |
Leslie DiRisio | Senior Vice President of Development Operations |
Ryan McHenry | Vice President and Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 7, 2025 | 8-K | Current Report |
Mar 24, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
Mar 24, 2025 | 424B5 | Filing |
Mar 24, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 24, 2025 | 10-K | Annual Report |
Mar 24, 2025 | 8-K | Current Report |
Feb 19, 2025 | 144 | Filing |
Feb 19, 2025 | 144 | Filing |
Feb 19, 2025 | 144 | Filing |
Feb 19, 2025 | 144 | Filing |